The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/23652
StudyName: Eligibility Small Cell Lung Cancer NCT02038647 DRKS00007849
Date of export from the portal: 02.07.2020
Date of Upload / last change: 10.07.2017
License: Creative Commons BY 4.0

----

Description: 
Responsible Party: 	Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: 	NCT02038647     History of Changes
Other Study ID Numbers: 	C14018
2013-003713-18 ( EudraCT Number )
U1111-1154-9805 ( Registry Identifier: WHO )
DRKS00007849 ( Registry Identifier: DRKS )
Study First Received: 	December 4, 2013
Last Updated: 	March 30, 2017

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02038647
